Olmesartan medoxomil plus hydrochlorothiazide for treating hypertension

Expert Opinion on Pharmacotherapy

Volumn 9, Issue 1, 2008, Pages 129-136

  Barrios, Vivencio ^a   Escobar, Carlos ^a  

^a HOSPITAL RAMÓN Y CAJAL   (Spain)

Author keywords

Angiotensin receptor blocker; Combination therapy; Hydrochlorothiazide; Hypertension olmesartan

Indexed keywords

ALDOSTERONE; ALISKIREN; AMLODIPINE BESYLATE; AMLODIPINE PLUS BENAZEPRIL; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GLUCOSE; HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; HYDROCHLOROTHIAZIDE PLUS LOSARTAN; HYDROCHLOROTHIAZIDE PLUS OLMESARTAN; HYDROCHLOROTHIAZIDE PLUS TELMISARTAN; HYDROCHLOROTHIAZIDE PLUS VALSARTAN; IRBESARTAN; LOSARTAN; OLMESARTAN; PLACEBO; RENIN; THIAZIDE DIURETIC AGENT; UNCLASSIFIED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; FLU LIKE SYNDROME; GLUCOSE BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPERURICEMIA; HYPOKALEMIA; HYPONATREMIA; LOW DRUG DOSE; METABOLIC DISORDER; MONOTHERAPY; OUTCOME ASSESSMENT; PROGNOSIS; RECOMMENDED DRUG DOSE; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REPEATED DRUG DOSE; RISK ASSESSMENT; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; VASODILATATION;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; DRUG COMBINATIONS; EXPERT TESTIMONY; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; IMIDAZOLES; TETRAZOLES; TREATMENT OUTCOME;

EID: 39049145136     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.9.1.129     Document Type: Article

References (52)

1. Ong KL, Cheung BM, Man YB, et al. Prevalence, awareness, treatment, and control of hypertension among United States adults 1999-2004. Hypertension 2007;49:69-75
2. Greathouse M. Olmesartan medoxomil combined with hydrochlorothiazide for the treatment of hypertension. Vasc Health Risk Manag 2006;2:401-9
3. Wang YR, Alexander GC, Stafford RS. Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med 2007;167:141-7
4. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of hypertension (ESH) and of the European society of cardiology (ESC). J Hypertens 2007;25:1105-87
5. European Society of Hypertension-European Society of Cardiology Guidelines Committee. 2003 European Society of Hypertension - European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21:1011-53
6. Barrios V, Escobar C, Calderon A, et al. CONTROLRISK Investigators. Cardiovascular risk profile and risk stratification of the hypertensive population attended by general practitioners and specialists in Spain. The CONTROLRISK study. J Hum Hypertens 2007;21:479-85
7. Motwani JG. Combining renin-angiotensin-aldosterone system blockade with diuretic therapy for treatment of hypertension. JRAAS 2002;3:72-8
8. Sica DA. Rationale for fixed-dose combinations in the treatment of hypertension: the cycle repeats. Drugs 2002;62:44-62
9. Mourad JJ, Waeber B, Zannad F, et al. Comparison of different therapeutic strategies in hypertension: a low dose combination of perindopril/indapamide versus a sequential monotherapy or stepped-care approach. J Hypertens 2004;12:2379-86
10. Barrios V, Escobar C, Divison JA, et al. Clinical experience with a low-dose fixed combination of perindopril plus indapamide in a primary-care setting: the PRETEND study. Therapy 2007;4:677-83
11. Poldermans D, Glazes R, Kargiannis S, et al. Tolerability and blood pressure-lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther 2007;29:279-89
12. Swedberg K, Cleland J, Dargie H, et al. Guidelines for the diagnosis and treatment of chronic heart failure: executive summary (update 2005): the Task Force for the Diagnosis and Treatment of Chronic Heart Failure of the European Society of Cardiology. Eur Heart J 2005;26:1115-40
13. Unger T. Pharmacology of AT1-receptor blockers. Blood Press 2001;10(Suppl 3):5-10
14. Kjeldsen SE, Os I, Høieggen A, et al. Fixed-dose combinations in the management of hypertension: defining the place of angiotensin receptor antagonists and hydrochlorothiazide. Am J Cardiovasc Drugs 2005; 5:17-22
15. Chrysant SG, Dimas B, Shiraz M. Treatment of hypertension with olmesartan medoxomil, alone and in combination with a diuretic: an update. J Hum Hypertens 2007;21:699-708
16. Laeis P, Püchler K, Kirch W. The pharmacokinetic and metabolic profile of olmesartan medoxomil limits the risk of clinically relevant drug interaction. J Hypertens Suppl 2001;19:S21-S32
17. von Bergmann K, Laeis P, Püchler K, et al. Olmesartan medoxomil: influence of age, renal and hepatic function on the pharmacokinetics of olmesartan medoxomil. J Hypertens Suppl 2001;19:S33-S40
18. Huber M, Bolbrinker J, Kreutz R. Pharmacokinetics and safety of olmesartan medoxomil in combination with glibenclamide in healthy volunteers. Clin Exp Hypertens 2006;28:631-43
19. Kreutz R, Bolbrinker J, Huber M. Pharmacokinetics of olmesartan medoxomil plus hydrochlorothiazide combination in healthy subjects. Clin Drug Investig 2006;26:29-34
20. Carter BL, Ernst ME, Cohen JD. Hydrochlorothiazide versus chlorthalidone: evidence supporting their interchangeability. Hypertension 2004;43:4-9
21. Püchler K, Laeis P, Stumpe KO. Blood pressure response, but not adverse event incidence, correlates with dose of angiotensin II antagonist. J Hypertens 2001;(Suppl 19):S41-S48
22. Neutel JM, Elliott W1, Izzo JL, et al. Antihypertensive efficacy of olmesartan medoxomil, a new angiotensin II receptor antagonist, assessed by ambulatory blood pressure measurements. J Clin Hypertens 2002;4:325-31
23. Brunner HR, Nussberger J. Relevance of clinical pharmacological models for the evaluation of therapeutic dose range of an AT1-receptor antagonist. J Hypertens Suppl 2001;19:S15-S20
24. Takai S, Miyazaki M. Effect of olmesartan medoxomil on atherosclerosis: clinical implications of the emerging evidence. Am J Cardiovasc Drugs 2006;6:363-36
25. Fliser D, Buchholz K, Haller H; European Trial on Olmesartan and Pravastatin in Inflammation and Atherosclerosis (EUTOPIA) Investigators. Antiinflammatory effects of angiotensin II subtype 1 receptor blockade in hypertensive patients with microinflammation. Circulation 2004;110:1103-7
26. Naya M, Tsukamoto T, Morita K, et al. Olmesartan, but not amlodipine, improves endothelium-dependent coronary dilation in hypertensive patients. J Am Coll Cardiol 2007;50:1144-9
27. Ball KJ, Williams PA, Stumpe KO. Relative efficacy of an angiotensin II antagonist compared with other antihypertensive agents. Olmesartan medoxomil versus antihypertensives. J Hypertens Suppl 2001;19:S49-S56
28. Stumpe KO, Ludwig M. Antihypertensive efficacy of olmesartan compared with other antihypertensive drugs. J Hum Hypertens 2002;16(Suppl 2):S24-S28
29. Chrysant SG, Marbury TC, Robinson TD. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension. J Hum Hypertens 2003;17:425-32
30. Chrysant SG, Marbury TC, Silfani TN. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate. Blood Press Monit 2006;11:135-41
31. Brunner HR, Arakawa K. Antihypertensive efficacy of olmesartan medoxomil and candesartan cilexetil in achieving 24-hour blood pressure reductions and ambulatory blood pressure goals. Clin Drug Investig 2006;26:185-93
32. Smith DH, Dubiel R, Jones M. Use of 24-hour ambulatory blood pressure monitoring to assess antihypertensive efficacy: a comparison of olmesartan medoxomil, losartan potassium, valsartan, and irbesartan. Am J Cardiovasc Drugs 2005;5:41-50
33. Oparil S, Williams D, Chrysant SG, et al. Comparative efficacy of olmesartan, losartan, valsartan, and irbesartan in the control of essential hypertension. J Clin Hypertens (Greenwich) 2001;3:283-91
34. Stumpe KO. Olmesartan compared with other angiotensin II receptor antagonists: head-to-head trials. Clin Ther 2004;26(Suppl A):A33-A37
35. Giles TD, Oparil S, Silfani TN, et al. Comparison of increasing doses of olmesartan medoxomil, losartan potassium, and valsartan in patients with essential hypertension. J Clin Hypertens (Greenwich) 2007;9:187-95
36. Fabia MJ, Abdilla N, Oltra R, et al. Antihypertensive activity of angiotensin II AT1 receptor antagonists: a systematic review of studies with 24 h ambulatory blood pressure monitoring. J Hypertens 2007;25:1327-36
37. Greathouse M. A review of olmesartan medoxomil monotherapy: antihypertensive efficacy similar to that of other angiotensin II receptor blocker/hydrochlorothiazide combinations?. Congest Heart Fail 2002;8:313-20
38. Chrysant SG, Weber MA, Wang AC, et al. Evaluation of antihypertensive therapy with the combination of olmesartan medoxomil and hydrochlorothiazide. Am J Hypertens 2004;17:252-9
39. Barrios V, Boccanelli A, Ewald S, et al. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study. Clin Drug Investig 2007;27:545-58
40. Sellin L, Stegbauer J, Laeis P, et al. Adding hydrochlorothiazide to olmesartan dose dependently improves 24-h blood pressure and response rates in mild-to-moderate hypertension. J Hypertens 2005;23:2083-92
41. Izzo JL Jr, Neutel JM, Silfani T, et al. Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker. J Clin Hypertens (Greenwich) 2007;9:45-8
42. Izzo JL Jr, Neutel JM, Silfani T, et al. Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study. J Clin Hypertens (Greenwich) 2007;9:36-44
43. Neutel JM, Smith DH, Weber MA, et al. Use of an olmesartan medoxomil-based treatment algorithm for hypertension control. J Clin Hypertens (Greenwich) 2004;6:168-74
44. Neutel JM, Smith DH, Silfani TN, et al. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension. J Hum Hypertens 2006;20:255-62
45. Rump LC, Ambrosioni E, Burnier M, et al. Initial combination therapy with olmesartan/hydrochlorothiazide in moderate-to-severe hypertension. J Hum Hypertens 2006;20:299-301
46. Fogari R, Zoppi A, Mugellini A, et al. Hydrochlorothiazide added to valsartan is more effective than when added to olmesartan in reducing blood pressure in moderately hypertensive patients inadequately controlled by monotherapy. Adv Ther 2006;23:680-95
47. Ram CV. Antihypertensive efficacy of angiotensin receptor blockers in combination with hydrochlorothiazide: a review of the factorial-design studies. J Clin Hypertens (Greenwich) 2004;6:569-77
48. Conlin PR, Spence JD, Williams B, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418-26
49. Quan A, Chavanu K, Merkel J. A review of the efficacy of fixed-dose combinations olmesartan medoxomil/hydrochlorothiazide and amlodipine besylate/benazepril in factorial design studies. Am J Cardiovasc Drugs 2006;6:103-13
50. Hasford J, Mimran A, Simons WR. A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002;16:569-75
51. Verdecchia P, Angeli F, Reboldi G. New-onset diabetes, antihypertensive treatment, and outcome. Hypertension 2007;50:459-60
52. van den Meiracker AH, Jan Danser AH. Aliskiren: the first direct renin inhibitor for hypertension. Curr Cardiol Rep 2007;9:470-76